Literature DB >> 15880379

Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.

John S Lam1, Oleg Shvarts, Jonathan W Said, Allan J Pantuck, David B Seligson, Michael E Aldridge, Matthew H T Bui, Xueli Liu, Steve Horvath, Robert A Figlin, Arie S Belldegrun.   

Abstract

BACKGROUND: The presence of histologic necrosis in the primary tumor of patients with renal cell carcinoma (RCC) has been suggested to be an important predictor of survival. The authors investigated the relation of tumor necrosis to other clinicopathologic factors known to be important prognostic indicators for patients with RCC.
METHODS: The records of 311 patients undergoing treatment for RCC were evaluated for basic clinicopathologic information including TNM classification, nuclear grade, Eastern Cooperative Oncology Group (ECOG) performance status (PS), disease recurrence, and survival. The presence and extent of histologic necrosis of the primary tumors was recorded and correlated with clinicopathologic factors, carbonic anhydrase IX and Ki-67 expression, disease recurrence, and survival.
RESULTS: The presence of necrosis in the primary tumor of patients with RCC compared with patients with RCC without necrosis was associated with higher T classification (P < 0.0001), the presence of lymph node disease (P = 0.009), the presence of metastases (P < 0.0001), higher grade (P < 0.0001), greater mean tumor size (P < 0.0001), an ECOG PS score > or = 1 (P = 0.007), higher University of California-Los Angeles Integrated Staging System (UISS) category (P < 0.0001), and higher Ki-67 expression (P < 0.0001). The extent of necrosis in the primary tumor was associated with the presence of lymph node disease (P = 0.009) and the presence of metastases (P < 0.0001), and correlated with higher T classification (sigma = 0.31, P < 0.0001), poorer ECOG PS (sigma = 0.18, P = 0.002), higher grade (sigma = 0.33, P < 0.0001), greater tumor size (sigma = 0.40, P < 0.0001), higher UISS category (sigma = 0.37, P < 0.0001), and higher Ki-67 staining (sigma = 0.32, P < 0.0001). Patients with the presence of necrosis in the primary tumor demonstrated a lower 5-year disease-specific survival compared with patients without necrosis in the primary tumor (36% vs. 75%; P < 0.0001). Multivariate analysis demonstrated that T classification (P < 0.0001), distant metastases (P < 0.0001), and ECOG PS (P < 0.0001) were independent predictors of DSS, whereas the presence of necrosis was not (P = 0.1100). Substratification into localized and metastatic disease demonstrated that the presence of necrosis was an independent predictor of survival in patients with localized (P = 0.025), but not metastatic (P = 0.44), disease. The extent of necrosis was not an independent predictor of survival (P > 0.05). Patients with the presence of necrosis in the primary tumor had a lower 5-year disease recurrence-free rate compared with patients without the presence of necrosis (62% vs. 92%, P < 0.0001).
CONCLUSIONS: The presence of necrosis in the primary tumor was associated with adverse prognostic factors such as high T classification, presence of lymph node disease and metastases, high grade, large tumor size, and poor ECOG PS. The extent of necrosis was found to be associated with the presence of lymph node disease and metastases and correlated with higher T classification, higher grade, greater tumor size, poorer ECOG PS, and higher UISS category. The presence of this histologic variant was an independent predictor of poor survival in patients with localized, but not metastatic, disease. In addition, Ki-67 expression served as a valuable surrogate marker for the presence of histologic tumor necrosis. Copyright 2005 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15880379     DOI: 10.1002/cncr.21127

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  32 in total

1.  Pathological implications of areas of lower enhancement on contrast-enhanced computed tomography in renal-cell carcinoma: additional information for selecting candidates for surveillance protocols.

Authors:  Miguel Villalobos-Gollás; Bernardo Aguilar-Davidov; Carolina Culebro-García; Martha O Gómez-Alvarado; Priscila Rojas-Garcia; Raúl Ibarra-Fombona; Norma Uribe-Uribe; Guillermo Feria-Bernal; Ricardo Castillejos-Molina; Mariano Sotomayor; Fernando Gabilondo; Francisco Rodríguez-Covarrubias
Journal:  Int Urol Nephrol       Date:  2012-05-22       Impact factor: 2.370

2.  Histologic coagulative tumour necrosis as a prognostic indicator of aggressiveness in renal, lung, thyroid and colorectal carcinomas: A brief review.

Authors:  Rosario Caruso; Antonino Parisi; Anna Bonanno; Domenica Paparo; Emilia Quattrocchi; Giovanni Branca; Marco Scardigno; Francesco Fedele
Journal:  Oncol Lett       Date:  2011-09-16       Impact factor: 2.967

3.  Necrosis is a consistent factor to recurrence of meningiomas: should it be a stand-alone grading criterion for grade II meningioma?

Authors:  Pedro Góes; Bruno Fernandes Oliveira Santos; Fernando Seiji Suzuki; Débora Salles; João Noberto Stávale; Sérgio Cavalheiro; Manoel Antônio de Paiva Neto
Journal:  J Neurooncol       Date:  2017-12-21       Impact factor: 4.130

Review 4.  Prognostic factors in renal cell carcinoma.

Authors:  Alessandro Volpe; Jean Jacques Patard
Journal:  World J Urol       Date:  2010-04-03       Impact factor: 4.226

Review 5.  Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data.

Authors:  Jacqueline M Speed; Quoc-Dien Trinh; Toni K Choueiri; Maxine Sun
Journal:  Curr Urol Rep       Date:  2017-02       Impact factor: 3.092

6.  Multiparametric magnetic resonance imaging for the differentiation of low and high grade clear cell renal carcinoma.

Authors:  F Cornelis; E Tricaud; A S Lasserre; F Petitpierre; J C Bernhard; Y Le Bras; M Yacoub; M Bouzgarrou; A Ravaud; N Grenier
Journal:  Eur Radiol       Date:  2014-08-13       Impact factor: 5.315

7.  Multiphasic contrast-enhanced MRI: single-slice versus volumetric quantification of tumor enhancement for the assessment of renal clear-cell carcinoma fuhrman grade.

Authors:  Hebert Alberto Vargas; Holly G Delaney; Eithne M Delappe; Ya Wang; Junting Zheng; Chaya S Moskowitz; Yongqiang Tan; Binsheng Zhao; Lawrence H Schwartz; Hedvig Hricak; Paul Russo; Oguz Akin
Journal:  J Magn Reson Imaging       Date:  2012-11-13       Impact factor: 4.813

Review 8.  The changing face of renal cell carcinoma pathology.

Authors:  Hakan Aydin; Ming Zhou
Journal:  Curr Oncol Rep       Date:  2008-05       Impact factor: 5.075

9.  Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma.

Authors:  Patrick E Teloken; R Houston Thompson; Satish K Tickoo; Angel Cronin; Caroline Savage; Victor E Reuter; Paul Russo
Journal:  J Urol       Date:  2009-09-16       Impact factor: 7.450

10.  Staging of renal cell carcinoma: Current concepts.

Authors:  John S Lam; Tobias Klatte; Alberto Breda
Journal:  Indian J Urol       Date:  2009 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.